5 results match your criteria: "University of Pennsylvania Health Sciences[Affiliation]"

Background: Orally and intravenously administered proton pump inhibitors have been shown to reduce rebleeding rates, surgery and transfusion requirement.

Aim: To compare lansoprazole intravenous and orally disintegrating tablet (Prevacid SoluTab) regimens with a pantoprazole intravenously administered regimen in sustaining intragastric pH >6.0.

View Article and Find Full Text PDF

Individual differences in nicotine intake per cigarette.

Cancer Epidemiol Biomarkers Prev

May 2003

Abramson Cancer Center and Department of Psychiatry, University of Pennsylvania Health Sciences and the Annenberg Public Policy Center, Philadelphia, Pennsylvania 19104, USA.

The increase in levels of blood nicotine that occurs from smoking a single cigarette, sometimes referred to as a "nicotine boost," is an individualized measure of how much nicotine has been extracted from smoking a cigarette. This study investigated the demographic, smoking status, and psychological predictors of nicotine boost in a sample of 190 treatment-seeking smokers. Boost was assessed by comparing plasma nicotine levels before and after participants smoked one of their own brand cigarettes ad libitum.

View Article and Find Full Text PDF

Elucidating the role of genetic factors in smoking behavior and nicotine dependence.

Am J Med Genet B Neuropsychiatr Genet

April 2003

Department of Psychiatry and Abramson Cancer Center, University of Pennsylvania Health Sciences, 3535 Market Street, Suite 1400, Philadelphia, PA 19104, USA.

Despite over a decade of intensive tobacco control efforts, a substantial proportion of the world's population continues to smoke. With advances in molecular biology and genomics technology, attention is focusing on the genetic basis of addiction to nicotine. The hope is that by better understanding the biology of nicotine addiction, novel prevention and cessation strategies can be developed and targeted to individuals most likely to benefit.

View Article and Find Full Text PDF

Mediating mechanisms for the impact of bupropion in smoking cessation treatment.

Drug Alcohol Depend

July 2002

Cancer Center and Department of Psychiatry, University of Pennsylvania Health Sciences, 3535 Market Street, Suite 4100, Philadelphia, PA 19104, USA.

Several studies have documented the effectiveness of bupropion for smoking cessation, yet little is known about the mechanisms by which it facilitates abstinence. In this placebo-controlled randomized trial. We examined whether bupropion's effects on cessation were mediated by changes in withdrawal and/or negative or positive affect (PA).

View Article and Find Full Text PDF

Approximately 50% of the variance in smoking behavior is attributable to genetic factors. Genes in the serotonin system are plausible candidates because of serotonin's role in mood regulation. The present study examined the association of smoking behavior with a polymorphism in the TPH gene, which codes for a rate limiting enzyme in the biosynthesis of serotonin.

View Article and Find Full Text PDF